ACRV
Acrivon Therapeutics, Inc.
2.10$
+1.0%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | +184.6% | +883.8% | +47.3% | +87.7% | -8.6% | |
| – | +16,466.7% | +339.6% | +431.7% | +23.0% | +3.0% | |
| – | -12.7% | +15.2% | – | – | – | |
| – | +3.5% | -567.1% | – | -70.0% | -199.5% | |
| – | +1,486.7% | +810.1% | -40.5% | +114.9% | -39.7% | |
| – | +1,486.7% | +59,427.7% | – | -202.1% | – | |
| – | – | – | – | – | – | |
| – | -100.0% | – | – | – | – | |
| – | +3,784.4% | -9.4% | -101.5% | – | -100.6% | |
| – | +137,929.6% | -171.5% | – | -45.0% | -53.0% | |
| – | – | – | – | – | – |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.